Breaking Down SG&A Expenses: AbbVie Inc. vs Merus N.V.

A Tale of Two Companies: SG&A Expenses Over Time

In the world of pharmaceuticals, understanding the financial health of a company is crucial. AbbVie Inc. and Merus N.V., two prominent players, have shown contrasting trends in their Selling, General, and Administrative (SG&A) expenses from 2014 to 2023. AbbVie, a giant in the industry, has seen its SG&A expenses grow by approximately 66% over this period, peaking in 2022. This increase reflects its expansive operations and strategic investments. In contrast, Merus N.V., a smaller biotech firm, has experienced a staggering 1,450% rise in SG&A expenses, albeit from a much smaller base. This growth highlights its aggressive push into the market, aiming to establish a stronger foothold. The data underscores the different strategies these companies employ, with AbbVie focusing on consolidation and Merus on expansion. Such insights are invaluable for investors and industry analysts alike.